These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33888149)

  • 1. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
    Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
    Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis.
    Hisada S; Takeuchi S; Tozawa T; Yamada Y; Ito Y; Kodera M
    J Dermatol; 2024 Oct; 51(10):1329-1334. PubMed ID: 38963343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
    Lee TH; Lee JS; Park S; Lee KA; Kim HS
    Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
    Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
    J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
    Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
    Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
    Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.
    Matsuda KM; Sugimoto E; Ako Y; Kitamura M; Miyahara M; Kotani H; Norimatsu Y; Hisamoto T; Kuzumi A; Fukasawa T; Sato S; Yoshizaki A
    J Dermatol; 2024 Jun; 51(6):741-751. PubMed ID: 38558171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Bae S; Allanore Y; Coustet B; Maranian P; Khanna D
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S15-21. PubMed ID: 21586213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.
    Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis.
    Abignano G; Mennillo GA; Lettieri G; Karadag DT; Carriero A; Padula AA; Del Galdo F; Khanna D; D'Angelo S
    J Rheumatol; 2021 Sep; 48(9):1422-1426. PubMed ID: 33452163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.
    Zekovic A; Damjanov N
    Rheumatol Int; 2017 May; 37(5):735-741. PubMed ID: 28271157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
    Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D
    Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Ferreira PL; Genrinho I; Santiago T; Carones A; Mazeda C; Barcelos A; Beirão T; Costa F; Santos I; Couto M; Rato M; Terroso G; Monteiro P
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis.
    Rosato E; Gigante A; Pellicano C; Villa A; Iannazzo F; Alunni Fegatelli D; Muscaritoli M
    Clin Rheumatol; 2022 Jun; 41(6):1687-1696. PubMed ID: 35149929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?
    Stamm L; Garaiman A; Becker MO; Bruni C; Dobrota R; Elhai M; Ismail S; Jordan S; Zampatti N; Tatu AM; Distler O; Mihai C
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.
    McMahan ZH; Frech T; Berrocal V; Lim D; Bruni C; Matucci-Cerinic M; Smith V; Melsens K; Proudman S; Zhang J; Mendoza F; Woods M; Khanna D
    J Rheumatol; 2019 Jan; 46(1):78-84. PubMed ID: 30442827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.
    Taş YM; Derviş Hakim G; Keskinoğlu P; Kenar G; Yarkan H; Zengin B; Can G; Önen F; Akkoç N; Birlik M; Akarsu M
    Turk J Gastroenterol; 2019 Mar; 30(3):234-241. PubMed ID: 30541712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.
    Pellicano C; Oliva A; Colalillo A; Gigante A; D'Aliesio E; Al Ismail D; Miele MC; Cianci R; Mastroianni CM; Rosato E
    Clin Exp Med; 2024 Sep; 24(1):225. PubMed ID: 39294494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention.
    Frech TM; Khanna D; Maranian P; Frech EJ; Sawitzke AD; Murtaugh MA
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S22-5. PubMed ID: 21586214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.